MET and non-small cell lung carcinoma: Although the patients with NSCLC were not evaluated, results suggested that EGFR may affect the phosphoinositide 3 kinase/protein kinase B/phospholipase Cγ pathway and subsequently lead to brain metastasis.21 Another study revealed that EGFR‐TKI therapy induced MET expression and phosphorylation, which may be associated with subsequent brain metastases in patients with NSCLC.22 While this relationship can only explain the increase in brain metastases after EGFR‐TKI treatment, it does not explain the relationship between EGFR mutations and baseline brain metastasis.